BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) today announced that management will
present at the following healthcare-focused investment banking
conferences in November 2017:
Credit Suisse 26th Annual Healthcare Conference
November 8, 2017 at
12:20 pm MT
Scottsdale, Arizona
To view the webcast follow
this link: INVA
at Credit Suisse
Stifel Nicolaus Weisel 2017 Healthcare Conference
November 15, 2017
at 10:15 a.m. ET
New York, NY
To view the webcast follow this
link: INVA
at Stifel
Both presentations will be available and archived on the investor
relations page of the Innoviva web site at: http://investor.inva.com/events.cfm.
About Innoviva
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA®, ANORO® ELLIPTA® and TRELEGY ELLIPTA®, which were jointly
developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is
eligible to receive associated royalty revenues from RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent
economic interest in future payments made by GSK for TRELEGY® ELLIPTA®
and earlier-stage programs partnered with Theravance BioPharma, Inc..
For more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005238/en/
Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief
Financial Officer
650-238-9640
investor.relations@inva.com
Source: Innoviva, Inc.
News Provided by Acquire Media